Actavis (ACT) - FREE Research Report

Wilkinson George Fred who is Pres-Actavis Specialty Brands at Actavis sold 24,217 shares at $165.00 on Dec. 2, 2013. Following this transaction, the Pres-Actavis Specialty Brands owned 15,412 shares meaning that the stake was reduced by 61.11% with the 24,217-share transaction.

The shares most recently traded at $145.10, down $19.90, or 13.71% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 6,200
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.1 million shares per day over the past 30 days. Actavis has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 62.01% year-to-date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

A Sale of Citrix Would Complete Multi-Year Effort for Activist Elliott Management

Ranking the Activists for Proxy Season 2016

Symantec to Buy LifeLock in $2.3 Billion Cybersecurity Transformation

Own a Piece of the Rock -- and Sun

Why Activist Investors Won't Touch the Big Buyout Shops